Printer Friendly

POLAR MOLECULAR CORP. ANNOUNCES AGREEMENT WITH THE DOW CHEMICAL CO.

 POLAR MOLECULAR CORP. ANNOUNCES AGREEMENT WITH THE DOW CHEMICAL CO.
 SAGINAW, Mich., Feb. 3 /PRNewswire/ -- Polar Molecular Corporation (PMC) (OTC: PMCX) announced that The Dow Chemical Company (NYSE: DOW) of Midland, Mich., has signed an option to license fuel additive technology developed by PMC. During the option period, Dow will assess the opportunities for this technology in the U.S. and certain overseas markets.
 As part of the agreement, Dow Chemical receives an option to acquire certain "Know-How" and licensing rights.
 Under specific test conditions, the PMC technology has demonstrated an ability to control combustion chamber deposits, and to reduce the octane requirement increase (ORI) which occurs in automobiles as they age.
 -0- 2/3/92
 /CONTACT: Mark L. Nelson of Polar Molecular Corporation, 517-790-4764/
 (PMCX DOW) CO: Polar Molecular Corporation; The Dow Chemical Company ST: Michigan IN: CHM SU: LIC


ML -- DE002 -- 5987 02/03/92 08:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:150
Previous Article:CYGNUS NAMES NEW PRESIDENT AND CEO FORMER CHIRON PRESIDENT JOINS TO LEAD COMMERCIALIZATION
Next Article:GENERAL SERVICES ADMINISTRATION BOARD OF CONTRACT APPEALS DISMISSES FEDERAL COMPUTER CORP. COMPANION APPEALS, SAYS GTSI
Topics:


Related Articles
UNIVAR CORP. EXTENDS PUT AGREEMENTS WITH THE DOW CHEMICAL CO. AND PAKHOED INVESTERINGEN B.V.
DOW CORNING BOARD APPROVES SETTLEMENT AGREEMENT
UNIVAR TO EXERCISE DOW CHEMICAL PUT OPTION
Dow and Asahi Announce Commercial Agreement For Slurry PE From INSITE* Technology
Dow and Sunol to Collaborate in Plant-Based Production of Antibody For Treating Cancer; Studies will compare plant-based and mammalian cell...
Dow Enters NIH Research Agreement to Develop Rapid Vaccine Production System.
Kereos and Dow sign licensing agreement for targeted imaging agents.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters